Matthew Biegler
Stock Analyst at Oppenheimer
(0.98)
# 3,589
Out of 4,718 analysts
77
Total ratings
23.88%
Success rate
-11.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $91.23 | +26.06% | 1 | Dec 10, 2024 | |
| ARVN Arvinas | Maintains: Outperform | $50 → $40 | $19.91 | +100.90% | 3 | Oct 31, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $25.69 | +106.31% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $16.06 | +105.48% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $3.13 | +538.98% | 7 | Sep 16, 2024 | |
| RLAY Relay Therapeutics | Downgrades: Perform | n/a | $4.57 | - | 6 | Sep 10, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $17 → $15 | $8.32 | +80.29% | 4 | Aug 13, 2024 | |
| ALLO Allogene Therapeutics | Assumes: Outperform | $13 → $11 | $2.16 | +409.26% | 1 | Aug 8, 2024 | |
| OLMA Olema Pharmaceuticals | Reiterates: Outperform | $30 | $5.50 | +445.45% | 4 | Aug 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Outperform | $114 → $125 | $89.54 | +39.60% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $17.63 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $4.92 | +184.55% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 → $10 | $1.74 | +474.71% | 6 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $5.80 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.87 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $12.20 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $15 | $0.23 | +6,490.51% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $6.79 | +268.19% | 1 | Jun 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.46 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.26 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $5.15 | +6,890.29% | 1 | Nov 30, 2022 |
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $91.23
Upside: +26.06%
Arvinas
Oct 31, 2024
Maintains: Outperform
Price Target: $50 → $40
Current: $19.91
Upside: +100.90%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $25.69
Upside: +106.31%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $16.06
Upside: +105.48%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.13
Upside: +538.98%
Relay Therapeutics
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $4.57
Upside: -
ORIC Pharmaceuticals
Aug 13, 2024
Maintains: Outperform
Price Target: $17 → $15
Current: $8.32
Upside: +80.29%
Allogene Therapeutics
Aug 8, 2024
Assumes: Outperform
Price Target: $13 → $11
Current: $2.16
Upside: +409.26%
Olema Pharmaceuticals
Aug 7, 2024
Reiterates: Outperform
Price Target: $30
Current: $5.50
Upside: +445.45%
Blueprint Medicines
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $89.54
Upside: +39.60%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $17.63
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $4.92
Upside: +184.55%
May 13, 2024
Reiterates: Outperform
Price Target: $15 → $10
Current: $1.74
Upside: +474.71%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $5.80
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.87
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $12.20
Upside: -
Aug 11, 2023
Maintains: Outperform
Price Target: $50 → $15
Current: $0.23
Upside: +6,490.51%
Jun 2, 2023
Initiates: Outperform
Price Target: $25
Current: $6.79
Upside: +268.19%
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.46
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.26
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $5.15
Upside: +6,890.29%